Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma
Open Access
- 8 February 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 815654
Abstract
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase expressed at early stages of normal development and in various cancers including ALK-positive anaplastic large cell lymphoma (ALK+ ALCL), in which it is the main therapeutic target. ALK tyrosine kinase inhibitors (ALK TKIs) have greatly improved the prognosis of ALK+ALCL patients, but the emergence of drug resistance is inevitable and limits the applicability of these drugs. Although various mechanisms of resistance have been elucidated, the problem persists and there have been relatively few relevant clinical studies. This review describes research progress on ALK+ ALCL including the application and development of new therapies, especially in relation to drug resistance. We also propose potential treatment strategies based on current knowledge to inform the design of future clinical trials.Keywords
Funding Information
- National Natural Science Foundation of China
- Science and Technology Project of Nantong City (MS12017003-2)
- Postdoctoral Science Foundation of Jiangsu Province (2019M660127, 2019K062)
- Natural Science Foundation of Nantong Municipality
This publication has 152 references indexed in Scilit:
- Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium studyThe Lancet Oncology, 2013
- MicroRNA 96 Is a Post-Transcriptional Suppressor of Anaplastic Lymphoma Kinase ExpressionThe American Journal of Pathology, 2012
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung CancersScience Translational Medicine, 2012
- IL-2R common γ-chain is epigenetically silenced by nucleophosphin–anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALKProceedings of the National Academy of Sciences, 2011
- The Tyrosine 343 Residue of Nucleophosmin (NPM)-Anaplastic Lymphoma Kinase (ALK) Is Important for Its Interaction with SHP1, a Cytoplasmic Tyrosine Phosphatase with Tumor Suppressor FunctionsJournal of Biological Chemistry, 2010
- Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)Proceedings of the National Academy of Sciences, 2008
- The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 ActivationCancer Research, 2008
- STAT3 as a target for inducing apoptosis in solid and hematological tumorsCell Research, 2008
- Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpointsNature, 2006
- Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3Proceedings of the National Academy of Sciences, 2006